Contact this trialFirst, we need to learn more about you.
EGFR Inhibitor
WSD0922-FU for Lung Cancer
Recruiting1 awardPhase 2
Cleveland, Ohio
"This trial is testing a new drug called WSD0922-FU on patients with advanced lung cancer. The patients must have already received a drug called Osimertinib as their first treatment and
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service